Brought to you by 
NaviCyte licenses rights to Memorial Sloan cell line
13 Jul 1999
Executive Summary
Navicyte has acquired an exclusive worldwide license to commercial applications of Memorial Sloan's Caco-2 cell line. The line is made up of human colon carcinoma cells and is used to predict how the body will absorb compounds in the GI tract.
Deal Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NaviCyte licenses rights to Memorial Sloan cell line
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice